IPGP vs NOVT: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
NOVT is the larger of the two ($3.97B market cap): the incumbent the market prices for continued execution (24.60x forward earnings, beta 1.70). IPGP is the smaller challenger ($2.53B), priced similarly on forward earnings (25.49x): more room to run, but more to prove. NOVT is expected to grow revenue faster (15% vs 8% next year) at a similar price (24.6x vs 25.49x forward earnings). The case for IPGP rests on its own driver (Industrial demand recovery): if you believe in that, IPGP fits; if you believe in what the numbers show today, NOVT does.
IPGP vs NOVT: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | IPGP | NOVT | What it tells you |
|---|---|---|---|
| Market cap | $2.53B | $3.97B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 25.49 | 24.60 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 63.21 | 79.58 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 1.01 | 1.70 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 0% of range | 7% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.17 | 2.45 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how IPGP and NOVT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IPGP and NOVT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IPGP and NOVT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does IPG Photonics (IPGP) do?
IPG Photonics designs and builds fiber lasers, amplifiers and complete laser systems, and it is unusually vertically integrated: it makes its own semiconductor diodes, specialty fiber and optical components rather than buying them. That integration is what let it undercut older laser technologies on cost and reliability two decades ago. Revenue is reported in two segments. Industrial Solutions, about 85% of sales, supplies lasers that fabricators, carmakers, battery makers and general manufacturers use to cut, weld, clean, mark and 3D-print metal. Advanced Solutions covers medical, micromachining, scientific and defense work, including the CROSSBOW counter-drone laser system sold under the IPG Defense name. The company earns money mainly on equipment sales to machine builders and end users, plus a smaller stream of service, parts and accessories.
What does Novanta (NOVT) do?
Novanta Inc. is a specialized technology company that designs and manufactures photonics, precision motion, and vision components and sub-systems, which it sells to original equipment manufacturers (OEMs) in medical and advanced industrial markets worldwide. Its products include laser scanning and beam-steering systems, precision motors and encoders, machine-vision components, radio-frequency and surgical technologies, and other embedded devices that go inside customers' larger machines. The company organizes itself into two reporting segments: Medical Solutions, which serves minimally invasive surgery, life sciences, and patient monitoring, and Automation Enabling Technologies, which serves robotics, industrial automation, laser materials processing, and semiconductor and electronics manufacturing. Medical end markets represent a bit over half of revenue and advanced industrial the rest.
IPGP vs NOVT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- IPGP drivers: Industrial demand recovery; Emerging growth products.
- NOVT drivers: Medical Solutions demand; Automation and robotics.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The biggest risk is the industrial capital-spending cycle. For NOVT, novanta trades at a high price-to-earnings multiple (about 80x trailing and 25x forward as of November 2026), so any shortfall in growth or margins can drive sharp share-price moves: the shares fell about 3% right after Q3 results, which came with a small cut to full-year adjusted EPS guidance and fourth-quarter EBITDA guidance below expectations, and ended about 25% lower over the month to November 20, 2026.
IPGP or NOVT: which should you pick?
If the story you believe is IPGP's (Industrial demand recovery), IPGP is the more direct way to own it; if it is NOVT's (Medical Solutions demand), NOVT is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IPGP and NOVT guides.
IPGP vs NOVT: the full fundamentals
IPGP. Analysts expect about $1.12 billion of revenue and roughly $1.93 of adjusted EPS for 2026, rising to about $1.21 billion and $2.33 in 2027. At $59.41 a share that is about 2.3 times sales and roughly 25 times forward earnings, while the trailing GAAP P/E is above 60 because reported profit is thin. Cash and short-term investments cover more than a third of the market value, and the stock sits at its 52-week low after peaking near $156, so the valuation rests on margins recovering toward historical levels, not on current GAAP earnings.
NOVT. Novanta still trades at a rich valuation, with a trailing price-to-earnings ratio near 80x and a forward multiple around 25x, down from about 30x forward in October after the shares fell roughly 25% in a month. GAAP earnings are held down by acquisition-related amortization, deal costs and stock compensation, so the company and analysts emphasize adjusted EPS, which beat consensus again in Q3 at $1.05 against $0.97 even as full-year adjusted EPS guidance was trimmed to about $3.69. Net debt of roughly $745 million after the Riverpoint deal is now part of the valuation picture.
Headline figures (approximate, November 2026): IPGP shows revenue (ttm) ~$1.11 billion, q3 2026 revenue ~$288 million (up ~15% YoY), q3 2026 eps $0.47 GAAP, $0.61 adjusted vs ~$0.49 estimate, gross margin (q3 2026) ~40.7% GAAP; ~38.7% TTM; Q4 guide 37% to 40% adjusted; NOVT shows revenue (ttm) ~$1.09 billion, q3 fy2026 revenue ~$305 million (up ~23% YoY), q3 fy2026 adjusted eps ~$1.05 vs ~$0.97 consensus, margins (gross / operating / net) ~44% / ~12% / ~5%.
The bottom line: IPGP vs NOVT
IPGP and NOVT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined IPGP and NOVT exposure against your real portfolio. It is not an investment adviser.
Wondering how IPGP or NOVT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about IPG Photonics
Ask Walnut's AI anything about IPGP and see how it fits what you own.
FAQ
What is the difference between IPGP and NOVT?
+
IPG Photonics designs and builds fiber lasers, amplifiers and complete laser systems, and it is unusually vertically integrated: it makes its own semiconductor diodes, specialty fiber and optical components rather than buying them. Novanta Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is IPGP or NOVT the better stock?
+
Neither is universally better. NOVT is the larger incumbent; IPGP is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, IPGP or NOVT?
+
On forward P/E (as of November 2026), IPGP trades at 25.49x and NOVT at 24.60x, so NOVT is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both IPGP and NOVT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of IPGP vs NOVT?
+
IPGP: The biggest risk is the industrial capital-spending cycle. IPG sells equipment, so a slowdown in metal fabrication, autos or EV battery investment shows up in orders within a quarter or two, and the company's own Q4 guidance range (adjusted EPS of $0.30 to $0.60) is wide. Chinese fiber-laser makers such as Raycus and Maxphotonics have taken share in low and mid-power lasers, and pricing pressure in China, the world's largest laser market, is the main reason margins sit well below the 50%-plus of its peak years; Q4 guidance for adjusted gross margin of 37% to 40% shows how much the Q3 figure leaned on tariff refunds. GAAP profit is thin (TTM net income of roughly $40 million on about $1.11 billion of revenue), so impairments, litigation costs or tariff changes swing reported earnings sharply; management itself has flagged trade and tariff uncertainty as a risk to the outlook. CROSSBOW carries export-control exposure. Lumibird Medical still requires approvals before it closes, and integrating a medical-device business is new territory for IPG. The Belarus sale also depends on regulatory approval. The share price has kept falling despite two straight earnings beats, down about 16% in the month to November 20, 2026, which shows how little the market is paying for the recovery so far. NOVT: Novanta trades at a high price-to-earnings multiple (about 80x trailing and 25x forward as of November 2026), so any shortfall in growth or margins can drive sharp share-price moves: the shares fell about 3% right after Q3 results, which came with a small cut to full-year adjusted EPS guidance and fourth-quarter EBITDA guidance below expectations, and ended about 25% lower over the month to November 20, 2026. A large share of revenue comes from advanced industrial and semiconductor-adjacent markets that are cyclical and can slow quickly when customers cut capital spending. The company depends heavily on acquisitions for growth, which brings integration, goodwill, and balance-sheet risk if deals underperform; after Riverpoint, debt is about $894 million against about $149 million of cash, and GAAP profit margins are thin at about 5%, with Q3 GAAP net income of only about $2 million. Because Novanta sells components embedded inside OEM products, it has customer-concentration and design-win risk, and results can be pressured by tariffs, supply-chain costs, and foreign-exchange swings given its global manufacturing and sales footprint.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IPGP or NOVT; figures are approximate and dated (as of November 2026). Verify current data before investing.